XSWX
BANB
Market cap7.09bUSD
Sep 17, Last price
77.95CHF
1D
1.30%
1Q
14.72%
Jan 2017
-13.68%
IPO
-25.94%
Name
Bachem Holding AG
Chart & performance
P/E
39.26
P/S
8.40
EPS
1.99
Div yield, %
1.09%
Shrs. gr., 5y
1.38%
Rev. gr., 5y
11.57%
Revenues
695m
+14.84%
Net income
149m
+23.74%
CFO
271m
+85.46%
Dividend
May 04, 20260.9 CHF/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bachem Holding AG is a global partner to pharmaceutical and biotechnology companies, supplying crucial products and services for every stage from early-stage research and clinical trials to full-scale commercialization. The company specializes in the creation, manufacturing, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide chemical entities (NCEs). Beyond these, Bachem also offers established commercial NCEs and generic medications. Its comprehensive service offerings include project oversight, quality assurance, regulatory compliance guidance, advanced analytical testing, GMP-compliant production, specialized research-grade manufacturing, and integrated supply chain solutions. The company, established in 1971, operates from its headquarters in Bubendorf, Switzerland.
Key people
Thomas Meier
Chief Executive Officer, Chairman of the Corporate Executive Committee · since 2020
Roland Schuermann
Chief Operating Officer, Member of the Corporate Executive Committee · since 2020
Jurgen Brokatzky-Geiger
Non-Executive Director · since 2009
Headquarters & legal address
Hauptstrasse 144
Bubendorf, BL 4416
CH
Bubendorf, BL 4416
CH
Other language
BACHEM HOLDING LTD
Other language
BACHEM HOLDING SA
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||